Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celsion Signs Licensing Agreement With Japanese Yakult Honsha For Liver Cancer Agent ThermoDox

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Columbia, Md.-based biotech firm Celsion signed a licensing agreement with Japan's Yakult Honsha covering Celsion's liposomal platform drug, ThermoDox, a heat-sensitive formulation of doxorubicin to treat liver cancer

You may also be interested in...



China State FDA Grants Clinical Trial Approval For Celsion's Phase III Liver Cancer Trials

SHANGHAI - China's State FDA granted clinical trial approval to Columbia, Md.-based Celsion to conduct Phase III trials in China as part of the company's global trial program for leading product ThermoDo.

China State FDA Grants Clinical Trial Approval For Celsion's Phase III Liver Cancer Trials

SHANGHAI - China's State FDA granted clinical trial approval to Columbia, Md.-based Celsion to conduct Phase III trials in China as part of the company's global trial program for leading product ThermoDo.

Celsion Initiates First International Licensing Deal With Japan’s Yakult For Liver Cancer Drug ThermoDox

TOKYO -Yakult Honsha Co. of Tokyo and Celsion of Columbia, Md., announced a licensing agreement for Celsion's liver cancer drug ThermoDox, marking Celsion's first international licensing deal

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel